Methylprednisolone reduces pain, emesis, and fatigue after breast augmentation surgery: a single-dose, randomized, parallel-group study with methylprednisolone 125 mg, parecoxib 40 mg, and placebo
| Autor: | Torleiv Haugen, Luis Romundstad, Audun Stubhaug, Harald Breivik, Jon Narum, Knut Chr. Skolleborg, Helge E. Roald |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
medicine.medical_specialty Sedation Breast Implants Mammaplasty Anti-Inflammatory Agents Placebo Methylprednisolone Fentanyl Double-Blind Method Parecoxib medicine Humans Local anesthesia Breast augmentation Glucocorticoids Fatigue Analgesics Cyclooxygenase 2 Inhibitors business.industry Isoxazoles Middle Aged Surgery Anesthesiology and Pain Medicine Anesthesia Postoperative Nausea and Vomiting Female medicine.symptom business Propofol medicine.drug |
| Zdroj: | Anesthesia and analgesia. 102(2) |
| ISSN: | 1526-7598 |
| Popis: | We compared methylprednisolone 125 mg IV (n = 68) and parecoxib 40 mg IV (n = 68) with placebo (n = 68) given before breast augmentation surgery in a randomized, double-blind parallel group study. Surgery was performed under local anesthesia combined with propofol/fentanyl sedation. Methylprednisolone and parecoxib decreased pain at rest and dynamic pain intensity from 1 to 6 h after surgery compared with placebo (mean summed pain intensity(1-6 h): methylprednisolone [17.25; 95% confidence interval [CI], 14.85-19.65] versus placebo [21.7; 95% CI, 19.3-24.1]; P0.03; parecoxib [15.25; 95% CI, 13.25-17.25] versus placebo; P0.001; mean summed dynamic pain intensity(1-6 h): methylprednisolone [22.7; 95% CI, 20.1-23.3] versus placebo [28.4; 95% CI, 26.0-30.8]; P0.01; parecoxib [20.9; 95% CI, 18.6-23.2] versus placebo; P0.001). Both rescue drug consumption and actual pain (all observations before and after rescue) during the first 6 h were similar in the two active drug groups and significantly reduced compared with placebo. Using a composite score of actual pain intensity and rescue analgesic use, the active drugs were significantly superior to placebo (P0.001 for both active drugs). Postoperative nausea and vomiting was reduced after methylprednisolone administration (incidence, 30%), but not after parecoxib (incidence, 37%), during the first 24 h compared with placebo (incidence, 60%; P0.001). Fatigue was reduced by methylprednisolone (incidence, 44%), but not by parecoxib (incidence, 59%), compared with placebo (incidence, 66%; P0.05). In conclusion, methylprednisolone 125 mg IV given before breast augmentation surgery had analgesic and rescue analgesic-sparing effects comparable with those of parecoxib 40 mg IV. Methylprednisolone, but not parecoxib, reduced nausea, vomiting, and fatigue. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|